Wakefit Innovations IPO Details with GMP Today and Analysis highlights a D2C leader in mattresses and furniture launching a ₹1,400 Cr book-built issue positioned within India’s broader IPO cycle stages and process.
The company Incorporated in 2016, the Bengaluru-based firm targets urban homes via online sales across 700 districts, now blending e-commerce with 125 offline stores. Its expansion comes amid a strong India bull market for consumer-facing IPOs.
Investors eye its 28% revenue jump amid recent losses narrowing, backed by Axis Capital, IIFL and Nomura as lead managers.
Wakefit IPO Timetable and Structure
Wakefit Innovations IPO
- Opens December 8, 2025
- Closing December 10
- Allotment by December 11
- Listing on BSE/NSE around December 15.
- Issue Price Band: ₹185 to ₹195 per share
Those following the grey market can compare sentiment here with live IPO GMP today data across issues.
The issue mixes fresh capital of ₹377.18 Cr (equity shares unspecified) and OFS of 4.67-4.68 Cr shares (₹1 face value) by promoters Ankit Garg (43.01% pre-issue holding) and Chaitanya Ramalingegowda plus VCs like Peak XV.
Reservation splits as QIBs ≥75% net offer, NII ≤15%, retail ≤10% of net offer. Lot size and price band remain pending announcement, with minimum retail bid likely aligning mainboard norms post-price reveal; beginners should revisit what an IPO bid means in practical terms and how many lots can be applied in an IPO.
Registrar MUFG Intime handles applications via UPI/ASBA, so retail buyers are expected to use the standard ASBA process in IPOs.
Wakefit Innovations IPO GMP Today and Market Sentiment
Wakefit Innovations IPO GMP today reads ₹0 as of November 30, 2025, showing flat grey market sentiment with no change tagged, implying listing at issue price sans premium.
| MP Date | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 04-12-2025 | 195 | ₹36 | ₹231 (18.46%) |
| 03-12-2025 | 195.00 | ₹36 | ₹231 (18.46%) |
| 02-12-2025 | 195.00 | ₹36 | ₹231 (18.46%) |
This contrasts with historical best-performing IPOs in recent years, where strong GMP often preceded sharp listing gains.
Pre-IPO buzz stays muted despite D2C growth narrative, contrasting high GMPs in similar consumer plays.
Track daily shifts as subscription nears, but anchor fundamentals over unofficial quotes for Wakefit Innovations IPO Details with GMP Today and Analysis.
Wakefit Innovations Business Model and Product Range
Wakefit sells mattresses, furniture (beds, sofas, wardrobes), furnishings directly online, cutting middlemen for competitive pricing.
Operations span five manufacturing facilities in Haryana, Karnataka, Tamil Nadu, with vertical integration from foam to delivery across 28 states.
Strengths include 8+ years scaling to ₹1,000+ Cr annual run-rate, omnichannel push (125 stores in 62 cities) and marketing via digital campaigns. Investors evaluating the stock should pair this overview with a structured framework on how to analyse an IPO fundamentally.
Financial Snapshot from DRHP
Restated numbers reveal revenue scaling: FY24 ₹986-1,305 Cr (21-28% YoY growth), 9M FY25 ₹741 Cr total income, but PAT swings from losses FY22-24 (-₹146 Cr to -₹15/-₹35 Cr) to ₹36 Cr profit in H1 FY25.
EBITDA turns positive FY24 at 7-7.9% margins (₹66-91 Cr), ROE -6.58%, debt/equity 0.53, net worth ~₹520-557 Cr.
Cash from ops volatile but improving, FY24 topline CAGR ~25% over 3 years signals volume traction in Wakefit Innovations IPO DRHP financials.
| Period | Revenue (₹ Cr) | PAT (₹ Cr) | EBITDA Margin |
|---|---|---|---|
| FY22 | 820 | -146 | Negative |
| FY23 | 1,017 | -15 | 6.5% |
| FY24 | 1,305 | -35 | 7% |
| 9M FY25 | 741 | +36 | 7.1% |
Funds Usage and Growth Plans
Net proceeds fund ₹31 Cr for 117 new COCO stores, ₹161 Cr lease rents for existing outlets, ₹15 Cr machinery, ₹108 Cr marketing and balance corporate needs.
No major debt repayment, focus accelerates offline from 125 stores, boosting D2C mattress revenue growth amid ₹1,400 Cr valuation bets.
Store expansion plans address urban penetration gaps versus pureplay peers like Pepperfry.
Peer Comparison and Valuation
Peers like Sheela Foam trade at higher multiples; Wakefit’s FY24 P/S ~2.5-3.5x implies fair pricing if profitability path ahead sustains. Valuations will ultimately mirror how the IPO listing price is decided from demand and book-building.
ROCE -0.68% lags but EBITDA positivity and 25% CAGR beat sector averages. Risks include cash burn from capex, competition in furnishings and execution of omnichannel shift.
Analysis Conclusion: Neutral stance suits short-term traders given ₹0 GMP and profitability path ahead uncertainties, but Subscribe for 2-3 years if backing D2C home recovery with 28% growth and store expansion plans execution. Skip if avoiding loss-making consumer bets, watch price band for entry and compare with other live and upcoming IPO oppurtunities before committing fresh capital.
